Dossier
clinicaltrials
trial early
CINC424A2X01B Rollover Protocol
Key claim: Patients previously treated with ruxolitinib or ruxolitinib plus panobinostat on Novartis or Incyte-sponsored studies who are judged to benefit from ongoing treatment are enrolled in a long-term safety rollover protocol.
Abstract
This is a long term safety study for patients that have been treated with either ruxolitinib or a combination of ruxolitinib with panobinostat, on a Novartis or Incyte sponsored study, who have been judged by the study Investigator to benefit from ongoing treatment.
Why this matters
Pending synthesis.